Search clinical trials for: 89Zr-J591

Total 156 results

Merck Sharp & Dohme LLC

Terminated

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Coronavirus Disease (COVID-19)

United States, Austria, Belgium
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
GlaxoSmithKline

Completed

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Neoplasms | Cancer

Netherlands
Crescendo Biologics Ltd.
University Medical Center Groningen

Active, not recruiting

A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions

Advanced and/or Metastatic Solid Tumours

Netherlands
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
University Medical Center Groningen

Withdrawn

89Zr-RO5323441 PET Imaging in Glioblastoma

Glioblastoma

Netherlands
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Terminated

89Zr-atezolizumab PET Scan and Lobular Breast Cancer (ImaGelato)

Lobular Metastatic Breast Cancer

Netherlands
VU University of Amsterdam

Completed

SLN in Colon Cancer Using a Multimodal Tracer

Sentinel Lymph Node

Netherlands
Weill Medical College of Cornell University

Completed

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

United States
Telix Pharmaceuticals (Innovations) Pty Limited
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
ImaginAb, Inc.
University of Hull

Recruiting

CD8 Minibody Repeatability Study (PRETZCEL)

Melanoma | Renal Cell Carcinoma

United Kingdom
Memorial Sloan Kettering Cancer Center

Withdrawn

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Multiple Myeloma
Weill Medical College of Cornell University

Completed

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

Prostate Cancer

United States
Aplagon Oy
TRACER Europe BV

Recruiting

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (CHASE)

Peripheral Arterial Occlusive Disease | Critical Limb Ischemia

Netherlands
University Medical Center Groningen

Completed

VEGF Early Imaging for Breast Cancer

Breast Cancer

Netherlands
University Medical Center Groningen

Completed

Clinical Value of 89Zr-trastuzumab PET

Metastatic Breast Cancer

Netherlands
Stanford University

Suspended

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pancreas Cancer

United States
University of Alabama at Birmingham

Withdrawn

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer (Panitumumab)

Metastatic Colon Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Pituitary Adenoma | Brain Cancer

United States
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC

Unknown

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Non Small Cell Lung Cancer

Netherlands
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China
Weill Medical College of Cornell University

Terminated

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Prostate Cancer

United States
Andrei Iagaru

Not yet recruiting

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head-and-neck Squamous Cell Carcinoma

United States
Boehringer Ingelheim

Terminated

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Multiple Myeloma

United States
University of Alabama at Birmingham

Recruiting

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States
Hoag Memorial Hospital Presbyterian

Recruiting

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Multiple Myeloma

United States
University Medical Center Groningen

Completed

Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)

Breast Cancer

Netherlands
University Medical Center Groningen

Completed

VEGF Imaging in Renal Cell Carcinoma (Renimage)

Renal Cell Carcinoma

Netherlands
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
Weill Medical College of Cornell University

Recruiting

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Prostate Cancer

United States
The Netherlands Cancer Institute
Daiichi Sankyo, Inc.

Not yet recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Lymphoma | Metastatic Malignant Solid Neoplasm

United States
University Medical Center Groningen
Regeneron Pharmaceuticals

Active, not recruiting

LAG3 PET Imaging in Advanced Solid Tumors

Metastatic Solid Tumor

Netherlands
University Medical Center Groningen
Novartis

Completed

Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (Everolimage)

Metastatic Renal Cell Carcinoma

Netherlands
University Medical Center Groningen
VHL Alliance

Completed

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (VHLimage)

Renal Cell Carcinoma | Von Hippel-Lindau Disease | Pheochromocytoma | Pancreatic Neuroendocrine Tumor | Hemangioblastoma

Netherlands
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; Broad Institute

Completed

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Prostate Cancer

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Leiden University Medical Center

Recruiting

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Neurofibromatosis 2

Netherlands
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cyst

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Renal Impairment | Healthy Volunteer

United States, Czechia, Hungary, Poland

Search clinical trials for: 89Zr-J591

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations